Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors

被引:65
作者
Hamby, JM [1 ]
Showalter, HDH [1 ]
机构
[1] Parke Davis Pharmaceut Res, Dept Chem, Ann Arbor, MI 48105 USA
关键词
angiogenesis; antiangiogenic; tyrosine kinase inhibitors; small molecules;
D O I
10.1016/S0163-7258(98)00053-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiogenesis is an exciting and promising new area of research. The concept that tumor cells are absolutely dependent upon neovascularization to grow and metastasize has opened the door to a multitude of new approaches and targets for developing anticancer therapies. These potential new antiangiogenic therapies offer the possibility for improved efficacy and reduced toxicity relative to conventional cancer treatments without the possibility of drug resistance. In particular, reports of small molecule inhibitors of tumor-promoted angiogenesis are appearing ever more frequently in the scientific literature. For this reason, the major focus of this review will be to cover small molecule inhibitors of tumor-promoted angiogenesis. The present review concentrates on selected literature, principally from mid-1996 to mid-1998, where there are sufficient biological data to support claims of antiangiogenic activities by small molecules. In addition, a historical background is presented and some of the important issues related to this field are (C) 1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:169 / 193
页数:25
相关论文
共 191 条
  • [1] VASCULAR REACTIONS OF NORMAL AND MALIGNANT TISSUES INVIVO .1. VASCULAR REACTIONS OF MICE TO WOUNDS AND TO NORMAL AND NEOPLASTIC TRANSPLANTS
    ALGIRE, GH
    CHALKLEY, HW
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1945, 6 (01) : 73 - 85
  • [2] Arbiser JL, 1997, DRUGS TODAY, V33, P687
  • [3] Curcumin is an in vivo inhibitor of angiogenesis
    Arbiser, JL
    Klauber, N
    Rohan, R
    van Leeuwen, R
    Huang, MT
    Fisher, C
    Flynn, E
    Byers, HR
    [J]. MOLECULAR MEDICINE, 1998, 4 (06) : 376 - 383
  • [4] An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo
    Asano, M
    Yukita, A
    Matsumoto, T
    Hanatani, M
    Suzuki, H
    [J]. HYBRIDOMA, 1998, 17 (02): : 185 - 190
  • [5] Antiangiogenic tumour therapy: will it work?
    Augustin, HG
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (06) : 216 - 222
  • [6] Beckett RP, 1996, EXPERT OPIN THER PAT, V6, P1305
  • [7] Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor
    Berlin, J
    Tutsch, KD
    Hutson, P
    Cleary, J
    Rago, RP
    Arzoomanian, RZ
    Alberti, D
    Feierabend, C
    Wilding, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 781 - 789
  • [8] Tumour regression after endostatin therapy
    Black, WR
    Agner, RC
    [J]. NATURE, 1998, 391 (6666) : 450 - 450
  • [9] Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
    Boehm, T
    Folkman, J
    Browder, T
    OReilly, MS
    [J]. NATURE, 1997, 390 (6658) : 404 - 407
  • [10] Borgström P, 1998, PROSTATE, V35, P1